DARPP-32 Lentiviral Activation Particles (h2): sc-400430-LAC-2
- Target species: human
- 200 µl of transduction-ready, high-titer CRISPR/dCas9 Lentiviral Activation Particles
- DARPP-32 Lentiviral Activation Particles (h2) is a synergistic activation mediator (SAM) transcription activation system designed to specifically and efficiently upregulate gene expression via lentiviral transduction of cells
- DARPP-32 Lentiviral Activation Particles (h2) contain the following SAM Activation elements: a deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, an MS2-p65-HSF1 fusion protein and a target-specific 20 nt guide RNA. They also contain the blasticidin, hygromycin and puromycin resistance genes
- Upon transduction, the SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by DARPP-32 Lentiviral Activation Plasmid (h2) and DARPP-32 Lentiviral Activation Plasmid (h22) target distinct regulatory regions of the PPP1R1B promoter. One or both designs may be available
- Following transfection, gene activation efficiency can be assayed by WB, IF or IHC using antibody: DARPP-32 Antibody (H-3): sc-271111
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
DARPP-32 Lentiviral Activation Particles (h2) | sc-400430-LAC-2 | 200 µl | $455.00 |
Human PPP1R1B encodes DARPP-32 (dopamine- and cAMP-regulated phosphoprotein of 32 kDa), a pivotal signaling integrator in medium spiny neurons that links dopaminergic and glutamatergic inputs to protein phosphatase-1 (PP1) regulation. Upon PKA-dependent phosphorylation, DARPP-32 inhibits PP1 to modulate downstream phosphorylation networks controlling synaptic plasticity, neuronal excitability, and transcriptional programs within the cAMP/PKA and dopamine receptor pathways, while alternate phosphorylation states couple to calcineurin and other kinases. Altered PPP1R1B/DARPP-32 signaling has been associated with neuropsychiatric and neurodegenerative phenotypes and with dysregulated oncogenic signaling in certain tumor contexts, reflecting its broad role in phosphorylation-dependent control of cellular state. Gene editing of PPP1R1B supports mechanistic studies of dopamine-mediated signal transduction, phosphatase/kinase balance, and pathway interrogation in neuronal models and disease-relevant cell systems.
DARPP-32 Lentiviral Activation Particles (h2) address this need by packaging the complete synergistic activation mediator (SAM) transcriptional activation system into transduction-ready, high-titer lentiviral particles, enabling efficient PPP1R1B upregulation across a broader range of human cell types.
DARPP-32 Lentiviral Activation Particles (h2) deliver all functional components of the synergistic activation mediator (SAM) system via lentiviral transduction. The system comprises three particle preparations co-transduced into target cells: one encoding catalytically inactive dCas9 (D10A and N863A mutations) fused to the VP64 transactivation domain with a blasticidin resistance gene; one encoding the MS2-p65-HSF1 fusion protein with a hygromycin resistance gene; and one encoding a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers with a puromycin resistance gene. Following lentiviral transduction and genomic integration of the expression cassettes, the SAM components are stably expressed and assemble at the target locus within the proximal promoter region upstream of the PPP1R1B transcriptional start site, where VP64, p65, and HSF1 act cooperatively to recruit endogenous transcriptional machinery and drive sustained upregulation of endogenous DARPP-32 expression. The use of nuclease-inactive dCas9 avoids the introduction of double-strand DNA breaks and preserves the native PPP1R1B genomic locus and regulatory architecture.
The lentiviral format offers several practical advantages: stable genomic integration supports heritable activation across cell divisions; high-titer particle preparations eliminate the need for in-house viral production; and compatibility with primary, non-dividing, and transfection-resistant cell types expands experimental accessibility. Successful transduction can be confirmed and enriched through triple antibiotic selection using puromycin, hygromycin, and blasticidin.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.